The salaries of RHIVA2 staff involved in the planning of the trial, running the initial training sessions and any follow up activity with the practices were assumed as pro rata of their stated salaries. Staff employed by the NHS and responsible for HIV testing were assumed to be paid average salaries for their scales, according to their qualifications and positions, using the NHS pay rates website. 1 An additional 20% was added to all salary costs to allow for the costs of pension and National Insurance contributions incurred by the NHS.
Staff time was estimated as cost per minute and was calculated as the staff annual salary divided by 99,000 minutes (220 days multiplied by 7·5 hours of work per day multiplied by 60 minutes). We assumed that staff effectively worked 220 days per year instead of 365 days. This was to account for annual leave, bank holidays and sick leave. We also assumed a week of 37·5 hours of work for five days, working 7·5 hours per day. Staff salaries varied by scale and qualification, and costs were weighted by the number of professionals.
HIV screening cost-effectiveness model: further details
For simplicity, migration is not explicitly modelled, but the constant incidence rate used in the model, taken from Public Health England (PHE) data, implicitly includes infections imported into Hackney from elsewhere.
HIV screening cost-effectiveness model: state variables For individuals in HIV infection stage :
HIV-infected individuals, undiagnosed stage 1. .4 HIV-infected individuals, diagnosed: first (short-term) phase: diagnosed when infection was at stage 1. . 5 HIV-infected individuals, diagnosed: second (long-term) phase: diagnosed when infection was at stage 1. . 5 Secondary HIV infections, from undiagnosed HIV-infected individuals in stage 1. .5 Secondary HIV infections, from diagnosed HIV-infected individuals in the first (short-term) phase who were diagnosed when infection was at stage 1. .5 Secondary HIV infections, from diagnosed HIV-infected individuals in the second (long-term) phase who were diagnosed when infection was at stage 1. .5
HIV screening cost-effectiveness model: model equations
The model structure using mathematical notation is shown in Figure S1 . Following infection, individuals progress through the three phases of infection (undiagnosed, diagnosed short-term and diagnosed long-term) and at a certain point in their infection, defined by the diagnosis rate, their infection is diagnosed and they move from undiagnosed to the short-term diagnosis phase. The corresponding differential equations for the model are shown below:
2. .4 ⁄ 1. .4 ⁄ ⁄ 1 1. .5 where is HIV incidence in Hackney, is proportion of HIV infections diagnosed at a general practice, is progression to the next undiagnosed infection stage for 1. . 4 and is set to zero for 5 because it is assumed all patients are diagnosed before (HIV-related) death. is background death rate, is rate of diagnosis in the absence of the intervention for those in HIV infection stages 1 to 4, which is set to zero for stage 1 (it is assumed that no diagnosis occurs during acute infection, and that diagnosis accompanies progression to stage 5 [CD4<200 cells/μL]). Diagnoses rates to are constrained to be equal.
is the progression rate from the first (short-term) phase of diagnosed HIV infection to the second (long-term) phase, which is set to one year and does not depend on the infection stage during which an individual is diagnosed. is the proportion who are diagnosed when in CD4 band who die before reaching the long-term phase of diagnosed infection ( 1. .5), which is set to zero for those with CD4 counts ≥350 cells/μL at diagnosis. For the intervention scenario, the rate of diagnosis is changed from .. to , where represents the diagnosis rate due to rapid HIV testing.
Secondary infections
Cumulative number of secondary infections over the time horizon is calculated as follows:
where , and refer to HIV transmission probabilities per partnership for male-to-female, female-to-male and MSM transmission respectively, from HIV-infected undiagnosed individuals in HIV stage . Baseline infectiousness of long-term diagnosed (i.e. before discounting due to ART) is set to be the infectiousness of the CD4 >500 and 350-500 cells/μL groups.
, and are proportions of those that are infected that are heterosexual males, heterosexual females and MSM, respectively. and are mean number of sexual partnerships formed per year for heterosexuals and MSM, respectively. and are proportion of sexual partnerships involving consistent condom use, for heterosexuals and MSM, respectively. represents prevalence of circumcision amongst male partners of those infected and represents the reduction in susceptibility to HIV acquisition for males that are circumcised.
represents the reduction in sexual behaviour among persons identified as HIV positive; represents the reduction in sexual infectivity due to ART. The proportion of individuals on ART is higher in lower CD4 bands, defined by parameter for short-term and for long-term diagnosed. HIV prevalence in the Hackney 15-59 year population is assumed to remain constant over the time horizon (assumed values shown in Table S2 ) and is defined as , for MSM, heterosexual women and heterosexual men, respectively.
The number of secondary infections generated in the model population over the time horizon was estimated by integrating the secondary infection equations over the time horizon. Number of secondary infections averted was calculated as the difference between this integral by running the model with diagnosis rates and proportion diagnosed in general practices estimated using the control arm data, and then using diagnosis rates fitted to the intervention arm data.
Estimates of proportions within each risk group are taken from reported exposure category and gender of newly diagnosed HIV patients in London, 2012. 2 Data for new diagnoses were chosen over those for people living with HIV/AIDS because they would better represent the future spectrum of diagnosed infections by risk group, rather than the past. As assumed elsewhere, due to data limitations, we did not include preferential mixing by HIV status, ethnicity or immigration status, nor did we consider differential condom use by HIV status. 3 We have not included potential protection through preexposure prophylaxis because despite its recently proven effectiveness in reducing transmission, 4 it is not currently funded by the NHS and its use in the UK remains low.
Impact of screening on HIV transmission
A successful screening intervention resulting in earlier diagnosis (as demonstrated in this trial by the larger number diagnosed, at higher CD4 counts, for the intervention arm) implies a public health impact of the intervention on onwards HIV transmission going beyond benefits to the diagnosed individual. Upon diagnosis, individuals are likely to modify their risk behaviour to a certain extent (fewer partners, increased condom use etc.) and have lower infectiousness (treatment reduces viral load and thus infectiousness, 5 lower rates of other sexually transmitted infections [which may increase infectiousness] as a result of reductions in risk behaviour). A comprehensive evaluation of this impact requires a full understanding of the HIV epidemic amongst all relevant risk groups (men who have sex with men [MSM], heterosexual migrants and non-migrants, injecting drug users [IDUs] ), using all relevant and available data on sexual behaviour and HIV epidemiology, as specific to Hackney as possible. Such an analysis has been attempted for The Netherlands 6, 7 but a similar exercise specific to the UK or even to London, is beyond the scope of this article.
As an alternative, our analysis captures transmission from those diagnosed to their sexual partners (secondary infections). We therefore do not capture onward transmissions from these secondary infections and consequently, our results will underestimate the full impact of improved HIV detection on onward HIV transmission to some extent.
Model fitting
Diagnosed HIV incidence and prevalence for Hackney have been relatively stable since 2008, 8 therefore we assumed a constant HIV incidence in the model. We first fitted the equilibrium state of the model to incidence in the control arm of the trial, using the calculation that the proportion of HIV-infected individuals in the model diagnosed in control and intervention general practices is . is the proportion of all HIV infections that are diagnosed in practices, is the number of control practices (equal to the number of intervention surgeries, n=20), and is total number of practices in Hackney. Using this number of HIV-positive individuals in the model, diagnosis rates for control and intervention practices were fitted to the number of infections diagnosed and the proportions diagnosed at each CD4 band for intervention and control practices. The model was fitted using maximum likelihood, with 95% credible intervals (95%CIs) from the profile likelihood. Given the short duration of acute infection compared to the overall long duration of asymptomatic HIV infection, it was assumed that no infections were diagnosed during the acute phase. It was also assumed that diagnosis rates for CD4 bands >500 cells/μL, 350-500 cells/μL, and 200-349 cells/μL are equal, since those who are diagnosed cannot know their CD4 status at this stage. For those with CD4 counts <200 cells/μL, we initially proposed a model with a diagnosis rate for this group. When fitting the model, the fitted values were equivalent to almost instantaneous diagnosis, with large 95%CIs, which we interpreted as reflecting rapid diagnosis in this stage due to high levels of symptomatic presentations. We therefore altered the model to allow for rapid diagnosis once this stage was reached. Once the model had been fitted to the control arm, a diagnosis rate for the intervention arm was estimated by fitting to the data on the number and CD4 counts of new diagnoses in the intervention arm in a similar way to that in the control arm.
Calculation of HIV healthcare costs
Cost data used are shown in Table S3 . ART costs were calculated from data on the cost of healthcare for HIV patients in London provided as part of a Freedom of Information (FOI) request made by Kevin Kelleher for the financial year 2013-14 (personal communication). FOI data were preferred for antiretroviral costs because the NHS pays less for antiretrovirals than indicated in the British National Formulary (BNF). The FOI dataset also provided information on healthcare costs for HIV patients other than antiretrovirals, but we used estimates from Beck et al 9 for these because more detail is provided on cost by CD4 count. It is assumed that each diagnosed HIV patient has four CD4 count and four viral load tests per year, and one ART resistance test preceding ART initiation. This one-off resistance test is averaged over an assumed 45 years lived with HIV infection. The cost of the HIV diagnostic test is omitted because this cost is part of the intervention and is another one-off cost of HIV infection which, when averaged over the patient's lifespan to calculate an estimate of annual HIV healthcare cost, is a very small cost. Future unrelated healthcare costs (i.e. non-HIV-related costs) are excluded from the analysis as they can lead to uninformative results (at the extreme, their inclusion can lead to the abandoning of all medical care being the most cost-effective approach 10 ). Costs were discounted at a rate 3·5% per year 11 using the standard discounting model where discounting factors are equal to 1 where is the discount rate, is the year in which the event occurs and is the baseline year (set to 2012).
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Costs were adjusted to 2012 prices.
where is healthcare and treatment costs for undiagnosed in stage ; are costs for diagnosed in the short-term phase, not receiving ART;
are costs for diagnosed in the short-term phase who are receiving ART; are costs for diagnosed in the long-term phase, not receiving ART; and are these costs for diagnosed in the long-term phase who are receiving ART. and are the proportions in stage on ART for diagnosed short-term and long-term phases, respectively. There is relatively little information available on how long-term HIV healthcare costs are related to CD4 count at diagnosis. Therefore we explored three plausible scenarios, where those diagnosed with late infection have higher healthcare costs. These are summarised in Table S4 and are based on findings reported by Beck et al 2011 9 (UK, Scenario 1) and those of Krentz and Gill 2012 13 (Canada, Scenarios 2 and 3). Beck et al 9 reported 21% higher costs for patients on ART who were diagnosed at CD4 ≤200 cells/μL. Scenario 1 has 25% rather than 21% higher costs for long-term diagnosed patients on ART and who were diagnosed at CD4 ≤200 cells/μL because our cost calculations include data from other sources for price of ART and HIV-related tests (details shown in Table S3 ). Krentz and Gill reported that, for patients accessing care in South Alberta between 1995 and 2010, direct medical costs remained 1.6 times higher for late presenters diagnosed with CD4 count ≤350 cells/μL many years after diagnosis. We therefore explored two scenarios: 2) treatment and care of long-term diagnosed at CD4 ≤350 cells/μL was weighted to be 1.6 times the cost of those diagnosed at >350 cells/μL; and 3) treatment and care of long-term diagnosed at CD4 ≤350 cells/μL was weighted to be 1.6 times the cost of those diagnosed at >350 cells/μL, with costs for those diagnosed at CD4 ≤200 cells/μL twice that for those diagnosed at 200-349 cells/μL. In each case, weights were calculated so that total costs of all long-term diagnosed should be the same as in Scenario 1, assuming proportions diagnosed in each CD4 band were as provided by PHE (unpublished data). Parameter values are shown in Table S4 .
Calculation of QALYs
QALYs gained under the intervention scenario, by reducing HIV-related mortality, improving the quality of life by diagnosing infected individuals earlier and averting secondary infections through earlier diagnosis, are calculated by estimating and comparing cumulative QALYs by running the model with intervention and control arm-specific parameters over the time horizon. QALYs are calculated by multiplying each state variable in the model by its associated QoL estimate (see parameter values, Table S2 ) and then integrating over the time horizon and comparing QALYs for the model population for control and intervention arm-fitted HIV diagnosis rates: 1 , where is the proportion of short-term diagnosed with CD4<200 cells/μL receiving ART. is QoL for infected individuals in the second (long-term) diagnosed phase which is assumed to be independent of CD4 band at diagnosis. QALYs were discounted at a rate 3·5% per year 11 using the standard discounting model where discounting factors are equal to 1 where is the discount rate and is the year in which the event occurs.
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A scenario of 1·5% per year was undertaken in sensitivity analysis 14 (Table S7) . To evaluate change in QALYs because of secondary infections averted due to the intervention, the QoL of secondary infections in the control scenario is compared with QoL of secondary infections in the intervention scenario plus the QoL of individuals who remain uninfected in the intervention scenario (i.e. secondary infections averted), who are assumed to have QoL=1. The model does not incorporate ageing and so the comparison QoL for uninfected individuals must be fixed as 1, and therefore does not account for reduction in QoL over time, with ageing. 15 This leads to a slight overestimation of QALYs gained to the intervention.
Choice of time horizon
A lifetime time horizon has not been chosen for this analysis because for this intervention, its benefits continue to accrue indefinitely (because the reduction in onward HIV transmissions has long-lasting effects). The cost-effectiveness model only tracks secondary HIV transmission events, so all benefits would be accrued over the lifetime of the sexual partners of those screened as part of the intervention. NICE recommends that the time horizon for an analysis should be, "long enough to reflect all important differences in costs or outcomes between the technologies being compared"
11
. In view of the atypical nature of this intervention, we have chosen 40 years as an appropriate time horizon, but the sensitivity of cost-effectiveness results to this assumption is explored in sensitivity analysis.
Sensitivity analysis
Baseline values provided in Table S2 are used for model runs to determine central outcome estimates, while the ranges provided in brackets are used for one-way sensitivity analysis for tornado plots and probabilistic sensitivity analysis which uses Latin Hypercube Sampling (LHS). 16 LHS parameters were varied independently of one another over 1000 simulations using uniform distributions for each varied parameter. Scenario analysis was used to explore the impact of parameters which may substantially affect model outcomes. These parameters are: reduction of sexual behaviour among persons upon diagnosis, HIV-related healthcare costs per year (to reflect the possibility of price reductions as antiretroviral drug patents expire), time horizon and QALY discount rate. A summary of parameters varied in the one-way and probabilistic sensitivity analyses and scenario analyses is given in Table S7 .
Supplementary Results

Costs for the RHIVA2 intervention
Only 32 of 40 participating surgeries claimed the enrolment incentive. Ninety-two health professionals attended the initial training sessions, including 29 general practitioners (GPs), 20 nurses, and 22 healthcare assistants (HCAs); and 87 staff completed competency-based training. On average, three rapid test kits were used per trainee per session, and two additional kits were used for demonstration purposes.
Model fit
The values of fitted model parameters are shown in Table S5 and evaluation of model fit is shown in Table S6. Table S5 shows the fitted parameter value used as the base case, with 95%CI generated by drawing 1000 samples from the posterior distribution and selecting the 2.5 th and 97.5 th percentile. These values were subsequently used in model sensitivity analysis as the plausible parameter range. For the control arm, the fitted parameters are the underlying incidence rate in Hackney and a single diagnosis rate for all those with CD4 counts greater than 200 cells/μL. We initially fitted the model with a separate diagnosis rate for those with low CD4 counts, but this parameter was not identifiable, with fits converging on ever-larger diagnosis rates at this stage of infection. This suggested that individuals with low CD4 counts are diagnosed almost immediately in this population, presumably due to other symptoms. When we fitted these two parameters (Table  S5) , the model had a good fit to the data (Table S6) . For the intervention arm we then fitted an additional diagnosis rate, or an increase in the baseline diagnosis rate, which led to more rapid diagnosis for individuals with CD4 counts greater than 200 cells/μL. This meant that the proportion of people diagnosed with low CD4 counts inevitably fell, resulting in a less good fit for this group (Table S6) , making a less good fit than in the control arm. The model structure cannot capture the full complexity of the infection and diagnosis process, and therefore cannot capture all the behaviour of the system, but the overall fit to the data is good. HIV stage duration parameters were not varied as part of the univariate sensitivity analysis because these parameters interact with HIV incidence and diagnosis rates, so change in the duration of any HIV infection stage would have resulted in altered incidence and diagnosis rates. Hence the sensitivity analysis was performed only on those parameters that would not alter the quality of the fit to the data. Figure S4 shows that reductions in ART costs do not meaningfully impact RHIVA2 ICER predictions. RHIVA2 becomes cost-effective and eventually cost-saving because diagnosing patients earlier averts the higher long-term healthcare costs associated with late-diagnosed infection. The cost of ART is only part of the healthcare costs associated with managing an HIV diagnosed patient, so ART prices do not heavily influence model predictions. Figure S4 also shows that setting the costs of testing to zero increases cost-effectiveness.
Sensitivity to potential ART price reductions and cost of the intervention
Supplementary Discussion
Strengths and weaknesses
Our study has a number of strengths. We have undertaken a full uncertainty analysis involving Tornado plots for univariable analysis and probabilistic sensitivity analysis (PSA) in order to provide 95%CIs, to provide a range for each model output to reflect the uncertainty in our model inputs. However, the input parameters varied for the PSA do not include every input for which there is uncertainty, because if all of these were varied simultaneously, there would be too much "noise" in the model outputs to differentiate the different results for our intervention and control scenarios (for example, durations of each HIV stage and rates of sexual partner change are model inputs that are not known precisely and likely to be heterogeneous, but these properties would not differ between intervention and control scenarios, and so these parameters are kept constant). For some of the more potentially influential model inputs, we conducted scenario analyses to explore how different assumptions changed the model outputs (Figure 4 ).
Our study also has some limitations, reflecting uncertainties regarding the values of inputs for modelling the transmission of a sexually transmitted disease. There is a paucity of data to inform HIV transmission parameters such as HIV infectiousness. Sexual behaviour data, while easier to obtain, is often subject to bias. Therefore our model structure, which only tracks secondary infections, as opposed to a full transmission model which accounts for all HIV transmissions, is probably justified but will slightly underestimate benefits of the intervention as tertiary HIV infections onwards are not included We have attempted to handle uncertainty in model inputs by exploring sensitivity in the univariate, multivariate and scenario analyses described above. In addition, the precise timing of antiretroviral price reductions due to generics is difficult to define. Finally, the QoL of uninfected individuals, required in the model to account for impact of reducing onward transmission, assumes a constant value of 1, which does not account for reduction due to ageing. This leads to a slight overestimation of the QALYs gained due to the intervention.
Our analysis is designed to evaluate the cost-effectiveness of the RHIVA2 trial. Evaluation of the impact of the intervention with roll out, and in different contexts and for different populations, is beyond the scope of this paper but is important future work. Costs of the intervention on roll out will decrease, as costs such as incentives may no longer apply. In regions where HIV prevalence is lower than in Hackney, the positive predictive value of the test will decrease and therefore the cost per additional patient newly diagnosed by the intervention will increase. Cost-effectiveness of the intervention may increase if rolled out to higher HIV prevalence areas, for example areas with large MSM populations, and conversely may be lower where HIV prevalence is lower. Figure S1
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Figure S2 Cumulative costs accrued by the RHIVA2 trial, over time, plot using baseline parameters as detailed in Table  S2 . The intervention is continued for 28 months only (the duration of the RHIVA2 trial). "Diagnosed" individuals (green line) accrue costs for the trial due to increased HIV healthcare costs because of earlier diagnosis, while some costs are saved by preventing secondary infections (blue line).
Figure S3
Ribbon plots of incremental cost-effectiveness ratio (ICER), cost in GBP(£) per QALY gained due to the RHIVA2 trial, over time. The central, black line is the plot using base case values of all model parameters. The blue shaded ribbon is the area between ICER estimates plotted using the lowest and highest plausible parameter range for A) incidence (new infections in Hackney per year, range: 69-143); and B) QoL multiplier for acute stage HIV infection (range: 0.6-0.95).
Figure S3A
Figure S3B
Figure S4 Scenario analysis exploring the sensitivity of model results to different assumptions regarding reduction in cost of ART upon patent expiry and a scenario of zero HIV screening costs. The NICE threshold for cost-effectiveness of £20,000-£30,000 is shown in yellow. 
Supplementary Tables
Costs of marginal increase in serology testing due to the RHIVA2 intervention
Cost of additional serology tests performed due to the RHIVA2 intervention Heterosexual (female to male) Acute HIV 0·20 (0·10-0·30) 20, [25] [26] [27] [28] Asymptomatic HIV † 0·02 (0·01-0·04) 20, [29] [30] [31] [32] [33] [34] [35] [36] Symptomatic HIV § 0·04 (0·01-0·06) 20, [29] [30] [31] [32] [33] [34] [35] [36] Heterosexual (male to female) Acute HIV 0·30 (0·10-0·40) 20, [25] [26] [27] [28] Asymptomatic HIV † 0·03 (0·02-0·05) 20, [29] [30] [31] [32] [33] [34] [35] [36] Symptomatic HIV § 0·06 (0·02-0·10) 20, [29] [30] [31] [32] [33] [34] [35] [36] Homosexual (male to male) Acute HIV 0·40 (0·20-0·50) 20, [25] [26] [27] [28] Asymptomatic HIV † 0·04 (0·03-0·06) 37, 38 Symptomatic HIV § 0·08 (0·03-0·15) 37, 38 Annual number of partners MSM 4·2 (2-10) 43, 44 Reduction in heterosexual HIV transmissibility due to male circumcision, % 50% (48-60%) [45] [46] [47] Reduction in sexual behaviour among persons identified as HIV positive, % 25% (0-50%) Assumptions regarding sexual behaviour change upon diagnosis (no change, 25% and 50% reductions) explored through scenario analysis Reduction in sexual infectivity due to ART, % 96% (50-99%) 
Quality of life multipliers
Acute HIV 0·89 (0·60-0·95) [49] [50] [51] [52] ..
Unidentified asymptomatic HIV 0·91 (0·85-0·95) [49] [50] [51] [52] ..
Identified asymptomatic HIV, first year
0·84 (0·80-0·90) [49] [50] [51] [52] [53] Identified asymptomatic HIV, subsequent years 0·89 (0·85-0·95) [49] [50] [51] [52] [53] Identified symptomatic HIV, not on ART 0·72 (0·70-0·80) [49] [50] [51] [52] Symptomatic HIV treated with ART 0·83 (0·82-0·87) [49] [50] [51] [52] Uninfected individuals 1 Assumption Discount rate for QALYs 3·5% NICE Table S3 Diagnosed short-term, not on ART: CD4≤200 cells/μL (stage 5) £6,466 ‡ Calculations based on costs shown in Table S3 ..
Diagnosed short-term, on ART: CD4>200 cells/μL (stages 1-4) £9,688 ‡ Calculations based on costs shown in Table S3 Diagnosed short-term, on ART: CD4≤200 cells/μL (stage 5) £12,133 ‡ Calculations based on costs shown in Table S3 .. ART -antiretroviral therapy; NICE -National Institute for Health and Care Excellence; PHE -Public Health England. Values in brackets denote ranges used in the probabilistic sensitivity analysis. * Parameter used in the fitting procedure to estimate HIV incidence in the borough of Hackney. ** This trial duration parameter changes the diagnosis rates within the model when modelling the intervention scenario. For the first 28 months that the model runs, diagnosis rates are set to , the HIV diagnosis rate for the intervention scenario, and then revert to , the control HIV diagnosis rate (see Table S5 Mathematical symbols: C -healthcare costs for long-term diagnosed, not on ART; C -healthcare costs for long-term diagnosed, on ART; 1..5 -HIV stages 1 to 5 (acute infection and CD4 bands ≥500, 350-499, 200-349, <200 cells/μL respectively). * Beck et al 9 reported 21% higher costs for patients on ART who were diagnosed at CD4 ≤200 cells/μL. Scenario 1 has 25% higher costs for long-term diagnosed patients on ART rather than 21% because our cost calculations include data from other sources for price of ART and HIV-related tests (details shown in Table S3 ). ** Calculations are based on the following proportions in each CD4 band at diagnosis: 18.7% (5.6%), 21.0% (9.7%), 21.8% (26.1%), and 38.6% (58.6%) in CD4 bands <200, 200-349, 350-499 and ≥500 cells/μL for patients on ART (not on ART) with CD4 count recorded within one year of diagnosis (PHE, unpublished data 2013). Asymptomatic HIV (female to male) 0·01-0·04 20, [29] [30] [31] [32] [33] [34] [35] [36] Symptomatic HIV(female to male) 0·01-0·06 20, [29] [30] [31] [32] [33] [34] [35] [36] Acute HIV (male to female) 0·10-0·40 20, [25] [26] [27] [28] Asymptomatic HIV (male to female) 0·02-0·05 20, [29] [30] [31] [32] [33] [34] [35] [36] Symptomatic HIV(male to female) 0·02-0·10 20, [29] [30] [31] [32] [33] [34] [35] [36] Acute HIV (male to male) 0·20-0·50 20, [25] [26] [27] [28] Asymptomatic HIV (male to male) 0·03-0·06 37, 38 Symptomatic HIV(male to male) 0·03-0·15 Fraction of men who are circumcised 5-25% 43, 44 Reduction in heterosexual HIV transmissibility due to male circumcision 48-60% [45] [46] [47] Reduction in sexual infectivity due to ART 50-99% 
Diagnosed long-term
0·85-0·95
49-52
Identified asymptomatic HIV, first year ..
0·80-0·90
49-53
Identified asymptomatic HIV, subsequent years 0·85-0·95 [49] [50] [51] [52] [53] Identified symptomatic HIV, not on ART 0·70-0·80 [49] [50] [51] [52] Symptomatic HIV treated with ART 0·82-0·87 [49] [50] [51] [52] Scenario analysis (shown in Table 2 
0·88 Assumption
ART -antiretroviral therapy; MSM -men who have sex with men; N/A -Not applicable; QoL -Quality of Life. * Scenarios represent a 50% and an 80% reduction in ART costs upon patent expiry, respectively. Reduction in ART costs is estimated to occur the year after patent expiry (assumed to occur in 2018).
